Get the Stockscreener App
0.8389
6.65%
-0.0598
After Hours:
.83
-0.0089
-1.06%
Hoth Therapeutics Inc stock is traded at $0.8389, with a volume of 321.16K.
It is down -6.65% in the last 24 hours and down -19.34% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$0.8987
Open:
$0.88
24h Volume:
321.16K
Relative Volume:
0.65
Market Cap:
$13.01M
Revenue:
-
Net Income/Loss:
$-12.16M
P/E Ratio:
-0.7879
EPS:
-1.0647
Net Cash Flow:
$-9.68M
1W Performance:
-9.15%
1M Performance:
-19.34%
6M Performance:
-51.37%
1Y Performance:
-17.75%
1-Day Range:
$0.83
$0.8932
1-Week Range:
$0.83
$0.9541
52-Week Range:
$0.6554
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.8389 | 13.94M | 0 | -12.16M | -9.68M | -1.0647 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics Launches OpenClaw AI for Accelerating Drug Discovery - Contract Pharma
Hoth Therapeutics launches AI platform for drug discovery By Investing.com - Investing.com India
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery - PR Newswire
EXCLUSIVE: Hoth Therapeutics Targets Faster Drug Discovery With New AI Platform - Benzinga
HOTH: Analyst Jason Kolbert Maintains Buy Rating with $5 Target Price | HOTH Stock News - GuruFocus
Hoth reports positive pharmacokinetic data for topical HT-001 By Investing.com - Investing.com Australia
Hoth reports positive pharmacokinetic data for topical HT-001 - Investing.com
Hoth Therapeutics Reports Positive Ht-001 Pk, Safety, And Clinical Activity Data In Cancer Patients With Egfr Therapy - TradingView
Cancer-rash cream shows no serious side effects, sustained response - Stock Titan
Hoth Therapeutics stock faces biotech volatility amid pipeline updates and market pressures - AD HOC NEWS
Hoth Therapeutics shares climb after expanding AI partnership with NVIDIA - MSN
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
Fed Meeting: Will Hoth Therapeutics Inc announce a stock splitMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Aug EndMonth: How much upside does Hoth Therapeutics Inc have2026 Setups & Advanced Technical Signal Analysis - baoquankhu1.vn
Hoth Therapeutics reports preclinical data on obesity treatment - Investing.com Nigeria
Hoth Therapeutics reports preclinical data on obesity treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model - PR Newswire
ETF Watch: Will Hoth Therapeutics Inc. benefit from rising consumer demandWeekly Profit Summary & Stock Portfolio Risk Control - baoquankhu1.vn
Market Outlook: Is Hoth Therapeutics Inc benefiting from innovation trendsPortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Published on: 2026-03-07 13:26:02 - baoquankhu1.vn
Jobs Data: Will Hoth Therapeutics Inc announce a stock splitPortfolio Performance Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Breakout Zone: Whats the fair value of Hoth Therapeutics Inc stockEarnings Recap Report & Capital Protection Trade Alerts - baoquankhu1.vn
Hoth Therapeutics (NASDAQ: HOTH) Is Heating Up – New Site Added - Bitget
Hoth Therapeutics Integrates OpenAI API to Advance HT-KIT Oncology Program for Mast Cell-Derived Cancers - geneonline.com
Analyst Maintains Buy Rating for Hoth Therapeutics (HOTH) | HOTH Stock News - GuruFocus
Hoth Therapeutics Deploys OpenAI API to Support Development of HT-KIT - Contract Pharma
Hoth Therapeutics deploys Openai API to advance development of orphan HT-KIT oncology program - marketscreener.com
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program - PR Newswire
EXCLUSIVE: Hoth Therapeutics Integrates OpenAI API To Support Drug Development For Aggressive Cancers - Benzinga
HOTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HOTH.O| Stock Price & Latest News - Reuters
Aug Selloffs: Is Hoth Therapeutics Inc stock trending bullishPortfolio Risk Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
HOTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Hoth Therapeutics adds clinical site for skin toxicity trial - Investing.com India
Hoth Therapeutics Expands Clinical Trial for Cancer Skin Toxicity Treatment - National Today
Hoth Therapeutics adds clinical site for skin toxicity trial By Investing.com - Investing.com Australia
Hoth Therapeutics accelerates HT-001 trial enrollment with new clinical site as patient demand increases - marketscreener.com
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES - PR Newswire
Performance Recap: Will Lufax Holding Ltd Depositary Receipt benefit from geopolitical trendsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
Aug Reactions: Whats the outlook for Hoth Therapeutics Incs sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Will Hoth Therapeutics Inc. announce a stock splitCPI Data & Technical Pattern Recognition Alerts - mfd.ru
HOTH Should I Buy - Intellectia AI
Is Hoth Therapeutics Inc. stock trending bullishJuly 2025 Spike Watch & Technical Pattern Recognition Alerts - mfd.ru
Hoth Therapeutics receives U.S. notice of allowance for novel exon-skipping therapy targeting allergic diseases - marketscreener.com
Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases - TradingView
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases - PR Newswire
Hoth’s obesity treatment outperforms semaglutide in preclinical study - Investing.com Australia
Why Hoth Therapeutics Inc. stock is a must watch in 2025Trade Volume Summary & Pattern Based Trade Signal System - mfd.ru
Hoth’s obesity treatment outperforms semaglutide in preclinical study By Investing.com - Investing.com Nigeria
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics - Intellectia AI
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Asianet Newsable
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):